Sun Pharmaceutical Industries Limited (SUNPHARMA) — Financial Results | 22 May 2025(2 announcements)
Sun Pharmaceutical reported FY25 revenue of ₹520,412 crores, up 9.0% YoY, with net profit of ₹109,290 crores and adjusted net profit of ₹119,844 crores up 19.0%. The company proposed a final dividend of ₹5.50 per share, adding to prior dividends, totaling ₹16.00 per share for FY25. Key growth drivers included strong performance in India formulation (13.7% growth) and Global Specialty (17.1% growth), supported by R&D investment of ₹32,484 crores (6.2% of sales). The Board approved results highlighting market share gains in India (8.3% in a ₹2,259 billion market) and US formulation growth (3.6% YoY).
Sun Pharmaceutical reported consolidated net profit of ₹87.22 crores for Q4 FY25, a 32% year-on-year increase from ₹65.97 crores in Q4 FY24, driven by strong revenue growth to ₹1,150 crores (+18% YoY). The company highlighted improved operational efficiency and margin expansion as key drivers of profitability.
About Sun Pharmaceutical Industries Limited (SUNPHARMA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when SUNPHARMA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track SUNPHARMA — Free💡 Ask AI about this filing
📊 More SUNPHARMA filings
- 🔴 Financial Results — 6 August 2026 Sun Pharmaceutical reported Q1 FY27 revenue of INR1,51,836 million, up 10.1% YoY, with net profit at...
- 🟡 Board Meeting — 31 July 2026 Sun Pharmaceutical Industries Limited announced that all resolutions proposed at its 34th Annual Gen...
- 🟡 Board Meeting — 31 July 2026 Sun Pharmaceutical Industries Limited held its 34th Annual General Meeting on 31 July 2026 via video...
- 🟡 Board Meeting — 31 July 2026 Sun Pharmaceutical Industries Limited approved unaudited Q1 FY27 standalone and consolidated financi...
- Announcement — 29 July 2026 Sun Pharmaceutical Industries Limited announced that it has received approval from Brazil's ANVISA t...
🔥 Also filed on 22 May 2025
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when SUNPHARMA files new disclosures
Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SUNPHARMA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research